Literature DB >> 11712092

Cytomegalovirus infection of extremely low-birth weight infants via breast milk.

J Maschmann1, K Hamprecht, K Dietz, G Jahn, C P Speer.   

Abstract

In addition to seroprevalence and transmission rate, the clinical symptoms of postnatal cytomegalovirus (CMV) infection in infants with a very low birth weight (VLBW; <1500 g; <32 weeks gestational age at birth) were assessed in a 3-year prospective study. CMV monitoring included serologic testing (of the mother and child) and virus culture and PCR (of samples of both breast milk and the infant's urine). Within 3 weeks of the initial virus detection in the infant, clinical and laboratory parameters were evaluated. Of 170 infants, no CMV transmission was found in the 80 infants of seronegative mothers and in the 3 infants of seropositive mothers who did not shed CMV DNA into breast milk. Transmission occurred in 33 of the 87 CMV-exposed infants, 16 of whom presented with such symptoms as hepatopathy, neutropenia, thrombocytopenia, and sepsis-like deterioration. Low birth weight and early postnatal virus transmission were risk factors for symptomatic infection. VLBW infants of CMV-seropositive mothers are at high risk of acquiring a symptomatic CMV infection postnatally via breast milk.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11712092     DOI: 10.1086/324345

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  32 in total

Review 1.  Cytomegalovirus transmission from breast milk in premature babies: does it matter?

Authors:  P Bryant; C Morley; S Garland; N Curtis
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2002-09       Impact factor: 5.747

2.  Freeze-thawing of breast milk does not prevent cytomegalovirus transmission to a preterm infant.

Authors:  J Maschmann; K Hamprecht; B Weissbrich; K Dietz; G Jahn; C P Speer
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-07       Impact factor: 5.747

3.  Accelerated postnatal head growth follows preterm birth.

Authors:  J Cockerill; S Uthaya; C J Doré; N Modi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-01-12       Impact factor: 5.747

Review 4.  Priorities for CMV vaccine development.

Authors:  Philip R Krause; Stephanie R Bialek; Suresh B Boppana; Paul D Griffiths; Catherine A Laughlin; Per Ljungman; Edward S Mocarski; Robert F Pass; Jennifer S Read; Mark R Schleiss; Stanley A Plotkin
Journal:  Vaccine       Date:  2013-10-13       Impact factor: 3.641

5.  Maternal cytomegalovirus-specific immune responses and symptomatic postnatal cytomegalovirus transmission in very low-birth-weight preterm infants.

Authors:  Elizabeth P Ehlinger; Emily M Webster; Helen H Kang; Aislyn Cangialose; Adam C Simmons; Kimberly H Barbas; Sandra K Burchett; Mary L Gregory; Karen M Puopolo; Karen P Puopolo; Sallie R Permar
Journal:  J Infect Dis       Date:  2011-10-07       Impact factor: 5.226

Review 6.  The use of antiviral drugs during the neonatal period.

Authors:  Richard J Whitley
Journal:  Clin Perinatol       Date:  2012-01-21       Impact factor: 3.430

7.  Transmission of murine cytomegalovirus in breast milk: a model of natural infection in neonates.

Authors:  Carol A Wu; Sara A Paveglio; Elizabeth G Lingenheld; Li Zhu; Leo Lefrançois; Lynn Puddington
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

Review 8.  Immune responses to congenital cytomegalovirus infection.

Authors:  Ilija Brizić; Lea Hiršl; William J Britt; Astrid Krmpotić; Stipan Jonjić
Journal:  Microbes Infect       Date:  2017-12-26       Impact factor: 2.700

9.  Human cytomegalovirus reactivation during lactation and mother-to-child transmission in preterm infants.

Authors:  Johannes Meier; Uta Lienicke; Edda Tschirch; Detlev H Krüger; Roland R Wauer; Susanna Prösch
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

Review 10.  Breast milk-acquired cytomegalovirus infection and disease in VLBW and premature infants.

Authors:  Tatiana M Lanzieri; Sheila C Dollard; Cassandra D Josephson; D Scott Schmid; Stephanie R Bialek
Journal:  Pediatrics       Date:  2013-05-27       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.